Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/dth.14647 http://scihub22266oqcxt.onion/10.1111/dth.14647 33296557!7883057!33296557     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33296557&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Dermatol+Ther 2021 ; 34 (1): e14647 Nephropedia Template TP {{tp|p=33296557|t=2021. Can rituximab be used in the treatment of pemphigus vulgaris during the COVID-19 pandemic?|pdf=|usr=}}{{33296557}} gab.com Text Can rituximab be used in the treatment of pemphigus vulgaris during the COVID-19 pandemic JO: Dermatol Ther http://www.kidney.de/pget.php?&tw=1&pmid=33296557 #FOAvip Rituximab is a monoclonal antibody that targets CD20, a B-lymphocyte antigen; that leads to a decline in the B-cell counts for at least a year. The patients who have received rituximab treatment in the previous 5 years with the diagnosis of pemphigus group of diseases at Cerrahpasa Medical Faculty were questioned for COVID-19 infection. A total of 48 patients were included in this study; only one male patient had COVID-19 infection which had a mild course. There is no significant difference in the total number of lymphocytes between patients who have received rituximab within the previous 5 years or last year. The number of lymphocytes is independent of the number of courses of rituximab treatment received. Therefore, we suggest that all pemphigus patients who have received rituximab treatment within the previous 5 years should be careful of the preventive measures against the COVID-19 infection irrespective of the number of treatment courses or the number of years which has passed since the treatment. The disease course was mild in the only infected patient. Thus, rituximab may be used in the treatment of pemphigus vulgaris during the COVID-19 pandemic if its use is necessary. Twit Text FOAVip Can rituximab be used in the treatment of pemphigus vulgaris during the COVID-19 pandemic ????Dermatol Ther http://www.kidney.de/pget.php?&tw=1&pmid=33296557 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33296557 #FOAvip English Wikipedia <ref>{{Cite pmid|33296557}}</ref> Can rituximab be used in the treatment of pemphigus vulgaris during the COVID-19 pandemic? #MMPMID33296557 Uzuncakmak TK; Ozkoca D; Askin O; Kutlubay Z Dermatol Ther 2021[Jan]; 34 (1): e14647 PMID33296557show ga Rituximab is a monoclonal antibody that targets CD20, a B-lymphocyte antigen; that leads to a decline in the B-cell counts for at least a year. The patients who have received rituximab treatment in the previous 5 years with the diagnosis of pemphigus group of diseases at Cerrahpasa Medical Faculty were questioned for COVID-19 infection. A total of 48 patients were included in this study; only one male patient had COVID-19 infection which had a mild course. There is no significant difference in the total number of lymphocytes between patients who have received rituximab within the previous 5 years or last year. The number of lymphocytes is independent of the number of courses of rituximab treatment received. Therefore, we suggest that all pemphigus patients who have received rituximab treatment within the previous 5 years should be careful of the preventive measures against the COVID-19 infection irrespective of the number of treatment courses or the number of years which has passed since the treatment. The disease course was mild in the only infected patient. Thus, rituximab may be used in the treatment of pemphigus vulgaris during the COVID-19 pandemic if its use is necessary. |*COVID-19[MESH] |*Pemphigus/diagnosis/drug therapy/epidemiology[MESH] |Adult[MESH] |Female[MESH] |Humans[MESH] |Immunologic Factors/adverse effects[MESH] |Male[MESH] |Middle Aged[MESH] |Pandemics[MESH] |Rituximab/adverse effects/*therapeutic use[MESH] |SARS-CoV-2[MESH]Can rituximab be used in the treatment of pemphigus vulgaris during th(epmc).pdf DeepDyve Pubget Overpricing